Skip to main content

Table 1 Characteristics of infants receiving at least one dose of palivizumab, by eligibility criteria

From: RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study

Characteristic Infants receiving palivizumab
Criterion 1 (N = 175/803) Criterion 2 (N = 25/174) Criterion 3 (N = 67/1804) Other (N = 24/21,650)
  n (%) n (%) n (%) n (%)
Sex
 Males 94 (53.7) 17 (68.0) 44 (65.7) 16 (66.7)
 Females 81 (46.3) 8 (32.0) 23 (34.3) 8 (33.3)
Year of birth
 2002–2009 17 (9.7) < 5 (< 20.0) 30 (44.8) 5 (20.8)
 2010–2013 158 (90.3) < 25 (< 100.0) 37 (55.2) 19 (79.2)
Indigenous status
 Aboriginal 20 (11.4) 25 (100.0) 6 (9.0) < 5 (< 20.8)
 Non-Aboriginal 155 (88.6) 0 61 (91.0) < 24 (< 100.0)
Gestational age
  < 28 weeks 175 (100.0) 25 (100.0) 12 (17.9) 16 (66.7)
 28–32 weeks 0 0 13 (19.4) < 5 (< 20.8)
 33–36 weeks 0 0 12 (17.9) < 5 (< 20.8)
  ≥ 37 weeks 0 0 30 (44.8) 5 (20.8)
Birth weight
  < 1500 g 175 (100.0) 25 (100.0) 24 (35.8) 17 (70.8)
 1500–2499 g 0 0 13 (19.4) < 5 (< 20.8)
 2500–2999 g 0 0 11 (16.4) < 5 (< 20.8)
 3000–3499 g 0 0 11 (16.4) < 5 (< 20.8)
  ≥ 3500 g 0 0 8 (11.9) < 5 (< 20.8)
Geographical area of birth*
 Metropolitan 125 (71.4) < 5 (< 20.0) 52 (77.6) 18 (75.0)
 Rural 35 (20.0) < 10 (< 40.0) < 15 (< 22.4) < 10 (< 41.7)
 Remote 14 (8.0) 12 (48.0) < 5 (< 7.5) < 5 (< 20.8)
Major congenital anomalies
 Yes 77 (44.0) 16 (64.0) 40 (59.7) 7 (29.2)
 No 98 (56.0) 9 (36.0) 27 (40.3) 17 (70.8)
Congenital heart disease
 Yes 157 (89.7) 18 (72.0) 67 (100.0) 0
 No 18 (10.3) 7 (28.0) 0 24 (100.0)
Chronic lung disease
 Yes 175 (100.0) 20 (80.0) 15 (22.4) < 5 (< 20.8)
 No 0 5 (20.0) 52 (77.6) < 24 (< 100.0)
Season of birth
 Spring 23 (13.1) < 5 (< 20.0) 13 (19.4) < 5 (< 20.8)
 Summer 30 (17.1) < 5 (< 20.0) 12 (17.9) < 5 (< 20.8)
 Autumn 66 (37.7) 10 (40.0) 24 (35.8) 10 (41.7)
 Winter 56 (32.0) 9 (36.0) 18 (26.9) 11 (45.8)
Multiple birth
 Singleton 135 (77.1) < 25 (< 100.0) 60 (89.6) < 24 (< 100.0)
 Multiple 40 (22.9) < 5 (< 20.0) 7 (10.4) < 5 (< 20.8)
Number of previous pregnancies
 0 62 (35.4) 9 (36.0) 18 (26.9) 8 (33.3)
 1 41 (23.4) < 5 (< 20.0) 23 (34.3) 6 (25.0)
 2 19 (10.9) < 5 (< 20.0) 8 (11.9) < 10 (< 41.7)
  ≥ 3 53 (30.3) 11 (44.0) 18 (26.9) < 5 (< 20.8)
Socioeconomic status
 0–10% (most dis) 29 (16.6) 7 (28.0) 9 (13.4) < 5 (< 20.8)
 10–25% 18 (10.3) < 10 (< 40.0) 10 (14.9) 7 (29.2)
 25–75% 96 (54.9) < 5 (< 20.0) 28 (41.8) 9 (37.5)
 75–90% 13 (7.4) 0 < 15 (< 22.4) < 5 (< 20.8)
 90–100% 8 (4.6) 0 < 5 (< 7.5) < 5 (< 20.8)
 Missing 11 (6.3) 7 (28.0) 0 0
Mother smoking during pregnancy
 Yes 29 (16.6) 13 (52.0) 9 (13.4) 5 (20.8)
 No 146 (83.4) 12 (48.0) 58 (86.6) 19 (79.2)
  1. *Missing for 1 infant receiving palivizumab
  2. *NOTE: (1) Cell sizes of less than 5 have been suppressed
  3. (2) Criterion 1: gestational age < 28 weeks and CLD; criterion 2: gestational age < 28 weeks and identified as Aboriginal; criterion 3: CHD but not in criterion 1 or criterion 2 group